Skip to content
Lyka Labs logo

Lyka Labs

LYKALABS NSE
₹77.42 1.58 (2.00%)
Market Cap
₹280 Cr

Lyka Labs (LYKALABS) share price was ₹77.42 at the 28 Oct 2026 close; market capitalisation ₹280 Cr; sector Healthcare. The share price fell 17.3% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 28.1% year on year to ₹42.31 Cr and net profit was ₹2.05 Cr, against ₹0.99 Cr a year earlier (compared with Jun 2025). Promoters held 58.45% of Lyka Labs in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 38/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹77.42 −16.23 −17.33% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹280 Cr
EBITDA
₹0.00
Return on Equity
-11.49%
Debt to Equity
0.53
Book Value
₹25.68
EPS (TTM)
−₹2.50
52W High
₹98.25
52W Low
₹44.10

Price-based figures as of 28 Oct 2026, 15:14 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Lyka Labs (this company)
₹77.42—280 Cr3.010.00%-11.49%-7.00%141 Cr-9 Cr
Median 8 companies₹1,561.5534.861,17,574 Cr4.690.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
38 Weak
Overall score
Data confidence 91/100
surveillance:ASM2

Category scores

Quality Weak 44
Returns, margins, earnings quality 22%
Valuation Poor 28
Cheap vs sector & own history 24%
Growth Poor 33
Sales & profit trajectory 9%
Financial Health Poor 22
Solvency, leverage, coverage 9%
Momentum Strong 85
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%
Capped: a governance trigger overrides the fundamentals here (surveillance:ASM2 ≤ 50).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company's working capital requirements have reduced from 32.4 days to 22.7 days

Weaknesses

5
  • Stock is trading at 2.79 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 8.29% over past five years.
  • Company has a low return on equity of -2.04% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Oscillators

BearishNeutralBullish

Bullish

Bearish
1
Neutral
6
Bullish
2

Overall

BearishNeutralBullish

Bearish

Bearish
7
Neutral
6
Bullish
6

Moving Averages

BearishNeutralBullish

Bearish

Bearish
6
Neutral
0
Bullish
4

Growth Rate

Revenue Growth
-6.25% lower than 3Y

change over 1 year

Net Income Growth
-232% lower than 3Y

change over 1 year

Cash Flow Change
176%

change over 1 year

EBITDA Margin Change
-99.93%

change over 1 year Operating margin 10.75% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
22.88
27.99
32.56
27.77
30.11
41.16
33.8
33.43
33.03
36.66
30.73
28.03
42.31
Expenses
20.24
23.82
25.69
25.75
26.4
36.21
28.61
29.35
29.35
39.2
29.08
34.48
37.76
Operating Profit
2.64
4.17
6.87
2.02
3.71
4.95
5.19
4.08
3.68
-2.54
1.65
-6.45
4.55
OPM %
11.54%
14.9%
21.1%
7.27%
12.32%
12.03%
15.36%
12.2%
11.14%
-6.93%
5.37%
-23.01%
10.75%
Other Income
0.38
-0.18
0.54
0.32
0.56
0.03
0.83
0.82
0.63
1.09
1.16
0.61
0.42
Interest
1.35
1.19
1.28
1.07
0.65
0.54
0.61
0.47
0.85
0.79
0.82
0.7
1.01
Depreciation
3.47
3.59
2.84
2.9
1.76
1.76
1.83
1.42
2.11
2.15
2.15
2.04
2.01
PBT
-1.8
-0.79
3.29
-1.63
1.86
2.68
3.58
3.01
1.35
-4.39
-0.16
-8.58
1.95
Tax %
7.22%
-22.78%
38.6%
28.22%
30.65%
28.36%
24.3%
32.89%
26.67%
-26.65%
-6.25%
-6.06%
-5.13%
Net Profit
-1.85
-0.49
1.78
-2.09
1.29
1.91
2.7
2.03
0.99
-3.22
-0.15
-8.07
2.05
EPS (₹)
-0.56
-0.15
0.54
-0.63
0.4
0.59
0.76
0.5
0.26
-0.94
0
-2.13
0.57
Figures in ₹ Crores

Profit & Loss

Particulars Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
166
130
110
60
71
61
86
194
93
111
138
128
138
Expenses
139
110
87
63
73
65
67
93
76
95
121
132
141
Operating Profit
28
20
23
-4
-2
-4
20
101
17
16
18
-3
-3
OPM %
17%
16%
21%
-6%
-2.7%
-6%
23%
52%
18%
14%
13%
-2.7%
-2%
Other Income
4
8
-2
4
1
-30
0
-4
-4
1
2
4
3
Interest
24
15
19
10
7
20
26
20
12
5
2
3
3
Depreciation
11
9
10
11
7
8
8
17
14
13
7
8
8
PBT
-3
4
-8
-20
-15
-62
-14
59
-13
-1
11
-12
-11
Tax %
31%
-5%
-19%
-5%
-59%
1%
-29%
35%
0%
182%
29%
-11%
—
Net Profit
-5
4
-7
-19
-6
-63
-10
38
-13
-3
8
-10
-9
EPS (₹)
-2.29
1.67
-2.51
-6.14
-1.97
-21.1
-4.03
13.59
-4.3
-0.75
2.24
-2.81
-2.5
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
22
22
22
28
28
29
29
29
31
33
36
36
Reserves
20
22
16
21
15
-43
-54
-15
15
35
69
57
Borrowings
137
121
126
113
96
141
163
130
75
59
39
49
Other Liabilities
100
77
88
67
76
73
52
42
31
30
32
33
Total Liabilities
279
242
252
229
216
200
190
186
152
157
176
175
Fixed Assets
122
104
133
116
108
105
98
94
68
58
85
87
CWIP
27
30
24
28
31
28
26
18
16
23
1
2
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
130
107
94
85
77
68
66
74
67
76
90
86
Total Assets
279
242
252
229
216
200
190
186
152
157
176
175
Figures in ₹ Crores

Cash Flow

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
27
12
31
11
27
5
9
79
9
2
2
5
Investing
37
17
-13
-3
-4
0
0
-6
7
-9
-12
-9
Financing
-60
-30
-19
-10
-23
3
-12
-63
-22
2
5
4
Net Cash Flow
4
-1
0
-3
-1
9
-3
10
-5
-6
-5
0
Free Cash Flow
55
28
18
7
23
4
8
72
15
-7
-10
-6
CFO/OP
97
60
143
-318
-1,462
-131
49
79
52
21
28
-159
Figures in ₹ Crores

Ratios

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
124
121
97
125
75
48
37
35
79
89
114
100
Inventory Days
77
56
90
139
65
69
41
56
68
78
82
99
Days Payable
220
218
266
301
216
192
141
96
91
98
98
122
Cash Conversion Cycle
-18
-41
-79
-37
-75
-76
-63
-5
55
68
97
76
Working Capital Days
-220
-242
-357
-735
-265
-242
-118
-121
0
23
51
23
ROCE %
10%
7%
9%
-8%
-5%
-6%
10%
61%
5%
4%
10%
-6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Lyka Labs insights

65 extracted metrics + investor summaries across FY09–FY27.

Shareholding Pattern

FIIs0.15%Promot.58.45%DIIs0.66%Others9.52%Public31.22%As ofSep 2026

Documents

Frequently Asked Questions about Lyka Labs

What does Lyka Labs Ltd do?
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]
Where is Lyka Labs Ltd (LYKALABS) listed?
Lyka Labs Ltd trades as LYKALABS on the NSE and under code 500259 on the BSE.
Which sector does Lyka Labs Ltd belong to?
Lyka Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Lyka Labs Ltd?
Lyka Labs Ltd has a market capitalisation of ₹279.89 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Lyka Labs Ltd?
Over the last 52 weeks Lyka Labs Ltd has traded between ₹44.1 and ₹98.25 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Lyka Labs Ltd?
Lyka Labs Ltd reported a return on equity of -11.49%. Its debt-to-equity ratio is 0.53.

Company Information

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Website lykalabs.com
CEO Mr. Kunal Narendra Gandhi
Employees 499
Listed 1995-02-08
Face Value ₹ 10
Shares Outstanding 3,61,52,711

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LYKALABS.md for Lyka Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month